Sartorius Aktiengesellschaft (SRT3.DE)
Healthcare · GER · Germany
Fundamentals
Valuation and ratings
Sartorius Aktiengesellschaft trades at EUR219.40, which is 56% above the EUR97.36 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 42 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 103.1 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
SRT3.DE dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | EUR0.740 | 1 |
| 2025 | EUR0.740 | 1 |
| 2024 | EUR0.740 | 1 |
| 2023 | EUR1.44 | 1 |
| 2022 | EUR1.26 | 1 |
| 2021 | EUR0.710 | 1 |
| 2020 | EUR0.360 | 1 |
| 2019 | EUR0.620 | 1 |
| 2018 | EUR0.510 | 1 |
| 2017 | EUR0.460 | 1 |
| 2016 | EUR0.380 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
SRT3.DE earnings and analyst estimates
Recommendation mix, 20 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions. The company serves the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
SRT3.DE passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is Sartorius Aktiengesellschaft (SRT3.DE) undervalued?
Against our discounted cash flow estimate of EUR97.36, SRT3.DE at EUR219.40 is 56% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
What is SRT3.DE's P/E ratio?
SRT3.DE trades at 103.1 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Sartorius Aktiengesellschaft (SRT3.DE) pay a dividend?
Yes. Sartorius Aktiengesellschaft yields 0.30% at the current share price. It has paid EUR0.740 per share over the trailing twelve months. It has paid a dividend in each of the last 26 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
The full research page for SRT3.DE, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.